|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
5P50CA094056-14
|
$1,264,315
|
$75,859
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-03
|
$3,469,664
|
$728,629
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Uncover the mechanisms regulating the biogenesis and decay of miRNAs in cancer
|
ZIA BC 011566
|
$497,942
|
$149,383
|
Gu, Shuo
|
CCR (NCI)
|
|
UCLA Tumor Immunology Training Program
|
3T32CA009120-38S1
|
$38,799
|
$7,760
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
UCLA Tumor Immunology Training Program
|
5T32CA009120-38
|
$467,412
|
$93,482
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Translational Research in Breast Cancer (SPORE)
|
1P50CA186784-01
|
$2,162,000
|
$129,720
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Transduction of T cells to improve migration to tumor
|
5R01CA116206-10
|
$264,095
|
$264,095
|
HWU, PATRICK
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-30
|
$617,613
|
$617,613
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-15
|
$2,093,826
|
$251,259
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
|
5P50CA093459-10
|
$2,133,882
|
$128,033
|
GRIMM, ELIZABETH
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-15
|
$1,847,930
|
$240,231
|
HERSCHMAN, HARVEY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
5R01CA140655-05
|
$301,641
|
$99,542
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-05
|
$301,641
|
$99,542
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The Antigen Targeting Core
|
ZIC BC 011030
|
$196,186
|
$98,093
|
Parkhurst, Maria
|
CCR (NCI)
|
|
Texas Center for Cancer Nanomedicine
|
5U54CA151668-05
|
$2,695,386
|
$1,132,062
|
GORENSTEIN, DAVID
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,321,954
|
$26,439
|
Cooper, Julia
|
CCR (NCI)
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
1F30CA180731-01A1
|
$29,498
|
$29,498
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
TCR Gene Modified T Cells for Adoptive Immunotherapy
|
5P01CA154778-04
|
$3,295,681
|
$1,812,625
|
NISHIMURA, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeting Translation Control in Malignant Glioma
|
5R01CA124756-08
|
$246,045
|
$246,045
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
Targeting Oncogene Expression to Skin in Transgenic Mice
|
5R01CA052607-22
|
$462,072
|
$462,072
|
ROOP, DENNIS
|
UNIVERSITY OF COLORADO DENVER
|
|
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS
|
5R01CA156690-05
|
$289,768
|
$289,768
|
OLTZ, EUGENE
|
WASHINGTON UNIVERSITY
|
|
Targeting epigenetic regulators using bacterial macromolecule delivery
|
1R01CA188382-01
|
$323,673
|
$323,673
|
FORBES, NEIL
|
UNIVERSITY OF MASSACHUSETTS AMHERST
|
|
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
|
1R21CA178674-01A1
|
$202,275
|
$101,138
|
ZANETTI, MAURIZIO
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
5R01CA154697-04
|
$460,508
|
$460,508
|
CURIEL, DAVID
|
WASHINGTON UNIVERSITY
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
2R01CA136551-06A1
|
$579,424
|
$289,712
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted siRNA NanoJackets for the Personalized Treatment of Breast Cancer
|
1U43CA186118-01
|
$223,896
|
$223,896
|
CARTER, CARLY
|
KEYSTONE NANO, INC.
|
|
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer
|
1R21CA179652-01A1
|
$169,106
|
$42,277
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-04
|
$307,951
|
$307,951
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeted Chemoprevention for Melanoma
|
5R01CA136667-05
|
$394,108
|
$394,108
|
ROBERTSON, GAVIN
|
PENNSYLVANIA STATE UNIVERSITY
|
|
T-T interactions between naive and memory CD8+ T cells
|
ZIA BC 011586
|
$43,402
|
$43,402
|
Klebanoff, Christopher
|
CCR (NCI)
|
|
T-cell receptor gene therapy for human papillomavirus-positive cancers
|
ZIA BC 011479
|
$197,133
|
$147,850
|
Hinrichs, Christian
|
CCR (NCI)
|
|
Synergistic chemo-siRNA combination therapy
|
5R01CA158300-04
|
$361,309
|
$361,309
|
WIENTJES, M
|
OPTIMUM THERAPEUTICS, LLC
|
|
Survivin-targeting miRNAs in erbB3 promotion of erbB2-positive breast cancer
|
1R03CA181918-01
|
$77,396
|
$38,698
|
LIU, BOLIN
|
UNIVERSITY OF COLORADO DENVER
|
|
Suppression of BCR-ABL by siRNA-loaded Nanoparticles for the Treatment of CML
|
5F31CA174298-02
|
$42,676
|
$42,676
|
GAVRILOV, KSENIYA
|
YALE UNIVERSITY
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-05
|
$2,795,193
|
$2,431,818
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
1U01CA183012-01
|
$465,641
|
$232,821
|
ZAIA, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
SPORE: Brain Tumore SPORE Grant
|
5P50CA097257-12
|
$2,161,996
|
$108,100
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE in Skin Cancer
|
1P50CA174523-01A1
|
$2,162,000
|
$86,480
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
SPORE In Prostate Cancer
|
5P50CA092629-14
|
$1,881,400
|
$206,954
|
SCHER, HOWARD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
SPORE in Lymphoma
|
5P50CA126752-08
|
$2,162,000
|
$518,880
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-13
|
$1,910,079
|
$191,008
|
DINNEY, COLIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
SPORE in Cervical Cancer
|
2P50CA098252-11
|
$2,162,000
|
$237,820
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Sleeping Beauty-Mediated microRNA Therapeutics for Metastatic Colorectal Cancer
|
1R21CA177051-01A1
|
$165,300
|
$82,650
|
MCIVOR, R
|
UNIVERSITY OF MINNESOTA
|
|
Silencing CD44v6 Expression Prevents Intestinal Tumor Growth
|
5R03CA167722-02
|
$72,508
|
$72,508
|
MISRA, SUNITI
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Sensitize Chemoresistant Breast Cancer by Nano-delivery of siRNA and Cisplatin
|
5F32CA168163-03
|
$56,978
|
$56,978
|
XU, XIAOYANG
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Seattle Cancer Consortium Breast SPORE
|
5P50CA138293-05
|
$2,150,779
|
$172,062
|
PORTER, PEGGY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors
|
5U54CA163167-04
|
$934,250
|
$102,768
|
HOLLAND, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer
|
5R01CA138701-05
|
$283,175
|
$84,953
|
LI, MIN
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS
|
5R01CA097250-11
|
$349,620
|
$174,810
|
WEILBAECHER, KATHERINE
|
WASHINGTON UNIVERSITY
|
|
RNA Therapeutics for Pancreatic Cancer
|
5K08CA142903-04
|
$151,821
|
$151,821
|
WHITE, REBEKAH
|
DUKE UNIVERSITY
|
Total relevant funding to Gene Therapy for this search: $46,781,139
|